deltatrials
Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04332341

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Sponsor: Case Comprehensive Cancer Center

Conditions Allogeneic Hematopoietic Cell Transplantation
Interventions Nicotinamide riboside (NR)
Updated 18 times since 2020 Last updated: Feb 16, 2026 Started: May 19, 2020 Primary completion: Jul 31, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04332341, this EARLY_PHASE1 trial focuses on Allogeneic Hematopoietic Cell Transplantation and remains actively recruiting participants. Sponsored by Case Comprehensive Cancer Center, it has been updated 18 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Jun 2024 · 7 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~May 2025 · 6 months · monthly snapshot~May 2025 – ~Feb 2026 · 9 months · monthly snapshot~Feb 2026 – present · 3 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting EARLY_PHASE1

  2. May 2025 — Feb 2026 [monthly]

    Recruiting EARLY_PHASE1

  3. Nov 2024 — May 2025 [monthly]

    Recruiting EARLY_PHASE1

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting EARLY_PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

    Status: Active Not Recruiting → Recruiting

▶ Show 13 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Nov 2023 — Jun 2024 [monthly]

    Recruiting EARLY_PHASE1

  3. Apr 2023 — Nov 2023 [monthly]

    Recruiting EARLY_PHASE1

  4. Feb 2023 — Apr 2023 [monthly]

    Recruiting EARLY_PHASE1

  5. Dec 2022 — Feb 2023 [monthly]

    Recruiting EARLY_PHASE1

    Status: Suspended → Recruiting

  6. Jul 2022 — Dec 2022 [monthly]

    Suspended EARLY_PHASE1

  7. May 2022 — Jul 2022 [monthly]

    Suspended EARLY_PHASE1

  8. Apr 2022 — May 2022 [monthly]

    Suspended EARLY_PHASE1

  9. Nov 2021 — Apr 2022 [monthly]

    Suspended EARLY_PHASE1

  10. Jan 2021 — Nov 2021 [monthly]

    Suspended EARLY_PHASE1

  11. Sep 2020 — Jan 2021 [monthly]

    Suspended EARLY_PHASE1

    Status: Not Yet Recruiting → Suspended

  12. Jul 2020 — Sep 2020 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  13. May 2020 — Jul 2020 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations